Trastuzumab；曲妥珠单抗
分子式：C6470H10012N1726O2013S42分子量：145.53KD
简介：Trastuzumab 是一种人源化单克隆抗体，其以高亲和力与 HER2 选择性结合。Trastuzumab 已被批准用于治疗 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌。
产品形式：蛋白原液 。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
质量标准：
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test：…………………………………. .<3EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件：-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件：干冰运输
使用建议：
提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(去离子无菌水(细胞培养用水))或者PBS（PBS(1X),细胞培养级）。
不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。
稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，
举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg（质量）/50mg/ml(浓度)=0.1ML，
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值，比如单次给药0.5MG，对应蛋白原液给药体积为10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液，可于2-8度冷藏避光保存不超过2周，不建议长期储存。
避免反复冻融，每次冻融蛋白活性会降低约5%左右。
生物活性（仅来自于公开文献，不保证其有效性）
|
描述 |
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.. |
|
靶点 |
ErbB2 |
|
体外 |
Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1 |
|
体内 |
Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice. |
相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
|
产品编号 |
品名. |
Target |
|
MB2806 |
aflibercept |
VEGFR |
|
MB2786 |
Alemtuzumab |
CD52 |
|
MB2787 |
Alirocumab |
PCSK9 |
|
MB2789 |
Avelumab |
PDL-1 |
|
MB2790 |
Atezolizumab |
PDL-1 |
|
MB2791 |
Bevacizumab |
VEGF |
|
MB2792 |
Cetuximab |
EGFR |
|
MB2803 |
Daratumumab |
CD38 |
|
MB2794 |
Denosumab |
RANK Ligand |
|
MB2023 |
Eculizumab |
补体蛋白(C5) |
|
MB2795 |
Etanercept |
TNF |
|
MB2797 |
Evolocumab |
PCSK9 |
|
MB2773 |
Infliximab |
TNF-α |
|
MB2769 |
Ipilimumab |
CTLA-4 |
|
MB2772 |
Matuzumab |
EGFR |
|
MB2766 |
Mepolizumab |
IL-5 |
|
MB2767 |
Nivolumab |
PD-1 |
|
MB2774 |
Obinutuzumab |
CD20 |
|
MB2776 |
Ofatumumab |
CD20 |
|
MB2777 |
Omalizumab |
IgE |
|
MB2781 |
Panitumumab |
EGFR |
|
MB2761 |
Pembrolizumab |
PD-1 |
|
MB2762 |
Pertuzumab |
HER2 |
|
MB2763 |
Ranibizumab |
VEGFR |
|
MB2938 |
Ramucirumab |
VEGFR |
|
MB2749 |
Rituximab |
CD20 |
|
MB2757 |
Secukinumab |
IL-17 |
|
MB2751 |
Tocilizumab/Atlizumab |
IL-6 receptor |
|
MB2784 |
Adalimumab |
TNF-α |
|
MB2758 |
Ustekinumab |
IL-12 |
用途及描述：仅供科研，严禁用于人体(For R&D Only)
备注：所有报价均已含国内快递费及发票费用。库存情况可能有所变动，请与我们销售人员确认为准，价格情况请直接联系我们销售人员。
我司所售出产品仅供于科研研究用途（非临床科研研究），每次销售产品行为都适用于我司网上所列明的。
CAS 号：180288-69-1
英文名字：曲妥珠单抗